ZURICH (Reuters) - Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company's bispecific antibody Glofitamab.
ZURICH (Reuters) – Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company’s bispecific antibody Glofitamab.
Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma.
The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023.
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
